louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03367104: Narrow QRS HF Patients Assessed by ECG Belt
Official title: Electrical Dyssynchrony in Narrow QRS Heart Failure Patients as Assessed by the ECG Belt
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Heart Failure
Cardiac Resynchronization Therapy
Lead sponsor: Allina Health System
Sponsor class: OTHER
First posted: 2017-12-08
Enrollment: 10
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Healthy subjects and those with heart failure (reduced ejection fraction) with QRS duration ≤ 130 ms.

Brief summary: The purpose of this study is to quantitate electrical dyssynchrony in heart failure (HF) patients with a narrow QRS complexes (≤ 130 ms) using the ECG Belt. This is a pilot study that is designed to provide data that can be used in designing and implementing a prospective study of cardiac resynchronization therapy (CRT) in narrow QRS patients selected and optimized using the ECG Belt.


Eligibility criteria: Inclusion Criteria:

* Subject (or their legal guardian) must be willing to provide informed consent for their participation in the study
* Subject ≥ 18 years old

Exclusion Criteria:

* Subject has unhealed-open wounds on the torso and/or has a history of severe allergic reactions from ECG electrode gel
* Subject is enrolled in a concurrent study that could confound the results of this study
* Subject is pregnant

Primary outcomes:
measure: Electrical dyssynchrony quantification
timeFrame: through acute study completion (~60 minutes)
Secondary outcomes:
Other outcomes:
Locations:
city: Saint Paul
country: United States
facility: United Heart & Vascular Clinic
state: Minnesota
Study officials:
affiliation: Allina Health System
name: Alan Bank, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06882304: PREVALENCE OF WHITE SPOT LESIONS IN ENAMEL AFTER ORTHODONTIC TREATMENT IN YOUNG ADULTS
Official title: PREVALENCE OF WHITE SPOT LESIONS IN ENAMEL AFTER ORTHODONTIC
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: White Spot Lesion
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2025-03-18
Enrollment: 368
Sex: ALL
Minimum age (years): 18
Maximum age (years): 30
Standard ages: ADULT
Observational model: OTHER
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: 1. Patients whose age between 18-30 years old consulting in the outpatient clinic.
2. Provide informed consent.
3. Co-operative patients approving to participate in the trial.
4. Both sexes are included
5. Egyptian

Brief summary: The aim of the study is to measure prevalence of enamel white spot lesions in enamel in young adults after orthodontic treatment.


Eligibility criteria: Inclusion Criteria:

1. Patients whose age between 18-30 years old consulting in the outpatient clinic.
2. Provide informed consent.
3. Co-operative patients approving to participate in the trial.
4. Both sexes are included
5. Egyptian -

Exclusion Criteria:

1. Patients under or over this age group.
2. Patients with other developmental defect, such as; fluorosis, amelogenesis imperfecta and syndromes associated with enamel formation defects.
3. Patient with MIH .
4. Refuse to participate in the study.

Primary outcomes:
measure: Prevalence of white spot lesions in enamel after orthodontic treatment in young adults
timeFrame: baseline
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
citation: Tufekci E, Dixon JS, Gunsolley JC, Lindauer SJ. Prevalence of white spot lesions during orthodontic treatment with fixed appliances. Angle Orthod. 2011 Mar;81(2):206-10. doi: 10.2319/051710-262.1.
citation: Akin M, Tezcan M, Ileri Z, Ayhan F. Incidence of white spot lesions among patients treated with self- and conventional ligation systems. Clin Oral Investig. 2015 Jul;19(6):1501-6. doi: 10.1007/s00784-014-1382-3. Epub 2014 Dec 13.
Clinical trial NCT02578004: Risk Factors for Pressure Ulcers
Official title: Case Control Study of the Risk Factors for Pressure Ulcers in Tunisian Patients
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Pressure Ulcers
Keywords: Difficult
environmental, microbial, immunological and genetic factors
significantly different
Lead sponsor: Centre Hôpital Universitaire Farhat Hached
Sponsor class: OTHER
First posted: 2015-10-16
Enrollment: 313
Sex: ALL
Minimum age (years): 19
Maximum age (years): 88
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: This prospective study consisted of 100 patients were having at least one wound of pressure ulcer that met the following inclusion criteria. Who followed in many departments (emergency, orthopedic, physical medicine) of three University Regional hospitals of Tunisia (Farhat Hached and Sahloul Sousse, Fattouma Bourguiba Monastir) were evaluated prospectively.

Brief summary: Development of pressure ulcer (PU) is complex and multifactorial. The association of a constituted PU and of clinical / biological major elements is demonstrated and justifies. Prevention of PU is an important health priority, one that requires clear identification of risk factors.


Eligibility criteria: Inclusion Criteria:

* presenting with at least of a wound and confirmed diagnosis of PU, age≥18 years old, bedridden, not feeds only and without trophic and mental disorders.

Exclusion Criteria:

* paediatric study populations, age \> 90 years old, allergy to wound products, malignant origin

Primary outcomes:
measure: Anthropometric characteristics
timeFrame: one hour
measure: Diabetes mellitus
timeFrame: one hour
measure: Dyslipidemia
timeFrame: one hour
measure: Renal failure
timeFrame: one hour
measure: Inflammatory parameter
timeFrame: one hour
measure: Endogenous inflammatory marker
timeFrame: one hour
measure: Markers of nutritional status
timeFrame: one hour
measure: Marker of lipid peroxidation
timeFrame: one day
measure: Antioxidant parameters
timeFrame: one day
measure: Total antioxidant status
timeFrame: one hour
measure: Determination of trace elements
timeFrame: one hour
measure: Nutritional status
timeFrame: 3 hours
measure: Nutritional risk
timeFrame: 3 hours
measure: A microbiological diagnosis
timeFrame: 3 days
measure: Proteomics
timeFrame: 2 days
measure: DNA extraction
timeFrame: 2 days
measure: Genotype for the MMP9-1562 C/T polymorphism
timeFrame: 1 days
measure: Genotyping of TNF- α G238A
timeFrame: 1 days
measure: Genotyping of TNF- α G308A
timeFrame: 1 days
Secondary outcomes:
Other outcomes:
Locations:
city: Sousse
country: Tunisia
facility: Latifa KHLIFI
Study officials:
References:
Clinical trial NCT01807104: Total Hip Arthroplasty (THA) Surgical Techniques Comparing the Direct Anterior Approach to the Posterior Approach
Official title: Prospective Randomized Single Center Clinical Evaluation of THA Surgical Techniques Comparing the Direct Anterior Approach to the Posterior Approach
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Osteoarthritis of the Hip
Keywords: Anterior Approach
Posterior Approach
Lead sponsor: Barrett, William, M.D.
Sponsor class: INDIV
Collaborators: name: Johnson & Johnson
First posted: 2013-03-08
Enrollment: 87
Sex: ALL
Minimum age (years): 20
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to compare the short term effectiveness and return to function of subjects undergoing primary Total Hip Arthroplasty using an Anterior Approach (incision on the front part of the hip joint) versus Posterior Approach (incision over back part of the hip joint).

Detailed description: The anterior approach may provide better early post-operative outcomes because there are fewer muscles at the front of the hip so the surgeon works between them rather than cutting through muscle fibers. However, the anterior approach is more difficult to access so usually requires a specialized table.

The posterior approach is easier to access, but the incision cuts through muscle fiber. This may lengthen recovery time. However, a specialized table, which can be quite expensive, is often not required.

Eligibility criteria: Inclusion Criteria:

1. Subject is able to or capable of providing consent to participate in the clinical investigation.
2. Subject is between the ages of 20-75 years, inclusive.
3. Subject requires a cementless, primary total hip arthroplasty for non-inflammatory degenerative joint disease (NIDJD)
4. Subject has sufficient bone stock for the hip replacement device.
5. Subject is a suitable candidate for the devices specified in the clinical investigation plan and is willing to be randomized to either surgical approach.

Exclusion Criteria:

1. Subject in the opinion of the Investigator has an existing condition that would compromise his /her participation and follow-up in this investigation.
2. Subject has had previous surgery on the affected hip.
3. Subject has significant osteoarthritis of the contra-lateral hip requiring a total hip arthroplasty within 12 months.

Primary outcomes:
measure: Returning to Quality of Life by Using Either Anterior Approach Versus Posterior Approach
timeFrame: 5 years
Secondary outcomes:
Other outcomes:
Locations:
city: Renton
country: United States
facility: Valley Orthopedic Associates
state: Washington
Study officials:
name: William P Barrett, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01400204: Naturalistic Study Into the Hangover Effects of MDMA
Official title: A Naturalistic Study Comparing the Hangover Effects of MDMA, Other Drugs, and Alcohol in a Sample of Recreational Polydrug Users
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Hangover
Keywords: hangover
next day effects
MDMA
Alcohol
Lead sponsor: Utrecht Institute for Pharmaceutical Sciences
Sponsor class: OTHER
First posted: 2011-07-22
Enrollment: 39
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Recreational poly-drug users who were guests at a privat New Years Eve party

Brief summary: The aim of the study is to compare hangover effects of MDMA users versus those who used other drugs, or alcohol only at New Year's Eve. The week after New Years Eve, every day participants complete a questionnaire about the presence and severity of potential hangover symptoms. At day 1, demographics and alcohol and drug use at New Years Eve were recorded. On day 7, the Brief Symptom Inventory (BSI) is completed to asses last weeks mood. After 4 weeks, after a drug-free week, the BSI is completed again to serve as a reference.

Detailed description: A convenience sample was invited by e-mail to participate in the study, via the organizer of a private New Years Party.It was attempted to include as much participants as possible. Hence, no sampling method was applied when recruiting participants.

Eligibility criteria: Inclusion Criteria:

* poly drug user
* 18+ years old

Exclusion Criteria:

* mental or physical illness

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Utrecht
country: Netherlands
facility: Utrecht University
Study officials:
affiliation: Utrecht University
name: Joris C Verster, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00318604: Plasma Circulating Deoxyribonucelic Acid (DNA) as a Response Marker
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Head and Neck Cancer
Esophageal Cancer
Keywords: plasma circulating DNA
hean and neck cancers
esophageal cancer
localized head and neck cancers
localized esophageal cancer
Lead sponsor: Far Eastern Memorial Hospital
Sponsor class: OTHER
First posted: 2006-04-27
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Time perspective: PROSPECTIVE

Brief summary: This study investigates whether the amount of circulating plasma DNA can be used as a response marker for anti-cancer treatment in treating gross tumors.


Eligibility criteria: Inclusion Criteria:

* Head and neck cancers
* Esophageal cancer
* Undergoing anti-cancer treatments

Exclusion Criteria:

* No distant metastasis

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Far Eastern Memorial Hospital
name: LeJung Wu, MD, DPhil
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04908904: Acute Effects of Cafestol on Glucose Metabolism in Subjects With Type-2-diabetes.
Official title: Acute Effects of Cafestol on Glucose Metabolism in Subjects With Type-2-diabetes.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Diabetes Mellitus, Type 2
Keywords: Diabetes Mellitus, Type 2
Lead sponsor: University of Aarhus
Sponsor class: OTHER
Collaborators: name: Aarhus University Hospital
First posted: 2021-06-01
Enrollment: 16
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: Acute, double-blinded, randomized, cross-over cafestol intervention study with sixteen participants with T2D participating in two OGTTs.

Detailed description: The study is an acute, double-blinded, randomized, cross-over intervention study with sixteen participants with T2D. Initially, a blood sample is obtained (t=-15 min) and at time point 0, the participants will ingest a tablet containing either 12 mg cafestol or placebo. Immediately hereafter an OGTT commences with ingestion of a 75 g glucose solution. In the following 3 hours blood samples are collected at time points 0, 15, 30, 60, 90, 120 and 180 min. The samples will be used for determination of plasma glucose, insulin and cafestol, as well as GLP-1 and GIP. After a one-week washout period, the subject will undergo the same set-up again, however now with the opposite intervention / placebo.

Eligibility criteria: Inclusion Criteria:

* Type 2 Diabetes defined by standard Danish guidelines
* HbA1c ≥48 mmol/mol unless successfully treated with antidiabetic drugs and/or diet/exercise intervention

Exclusion Criteria:

* In treatment with insulin
* Pregnancy
* Planned pregnancy
* Breastfeeding
* Significant comorbidity expected to unable the subject from completing visits

Primary outcomes:
measure: Area under the curve for glucose
timeFrame: -15 to 180 minutes from ingestion of intervention/placebo capsule and 75 g. glucose solution
Secondary outcomes:
measure: Area under the curve for insulin-response
timeFrame: -15 to 180 minutes from ingestion of intervention/placebo capsule and 75 g. glucose solution
measure: Area under the curve for cafestol
timeFrame: -15 to 180 minutes from ingestion of intervention/placebo capsule and 75 g. glucose solution
measure: Area under the curve for GLP-1
timeFrame: -15 to 180 minutes from ingestion of intervention/placebo capsule and 75 g. glucose solution
measure: Area under the curve for GIP
timeFrame: -15 to 180 minutes from ingestion of intervention/placebo capsule and 75 g. glucose solution
Other outcomes:
Locations:
city: Aarhus
country: Denmark
facility: Steno Diabetes Center Aarhus
state: Aarhus N
Study officials:
References:
Clinical trial NCT02150304: Aminophylline Prophylaxis For Postdural Puncture Headache
Official title: Phase IV Study of Intravenous Aminophylline During Spinal Anesthesia
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Postdural Puncture Headache
Lead sponsor: Diskapi Yildirim Beyazit Education and Research Hospital
Sponsor class: OTHER_GOV
First posted: 2014-05-29
Enrollment: 100
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: patient records form who experinced headache after caserean section with spinal anesthesia were retrospectively evaluated

Brief summary: postdural puncture headache is a rare but serious complication of spinal anesthesia. many drugs were studied in prevention or treatment of that complication. However, there are limited numbers of trials about intravenous aminophylline for prevention. because of that we retrospectively aimed to investigate the effectiveness of aminophylline for postdural puncture headache in cesarean section.

Detailed description: retrospective trial about the effect of intravenous aminophylline for prevention of PDPH after caserean section with spinal anesthesia

Eligibility criteria: Inclusion Criteria:

* patients aolder than 18 years old

Exclusion Criteria:

* conversion to general anesthesia

Primary outcomes:
measure: postdural puncture headache
timeFrame: postoperative 2 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Ankara
country: Turkey
facility: Dışkapı Yıldırım Beyazıt Education and Research Hospital
Study officials:
affiliation: dışkapı yıldırım beyazıt education and research hospital
name: ibrahim öztürk, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
citation: Naghibi K, Hamidi M. Prophylactic administration of aminophylline plus dexamethasone reduces post-dural puncture headache better than using either drug alone in patients undergoing lower extremity surgery. Adv Biomed Res. 2014 Jan 9;3:5. doi: 10.4103/2277-9175.124631. eCollection 2014.
citation: Basurto Ona X, Uriona Tuma SM, Martinez Garcia L, Sola I, Bonfill Cosp X. Drug therapy for preventing post-dural puncture headache. Cochrane Database Syst Rev. 2013 Feb 28;2013(2):CD001792. doi: 10.1002/14651858.CD001792.pub3.
Clinical trial NCT03611504: Hemospray in Gastrointestinal Bleeding: A Real-life Multicenter Cohort
Official title: Hemospray Effectiveness and Predictors of Rebleeding in Patients With Gastrointestinal Hemorrhage: A Real-life Multicenter Cohort.
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Gastrointestinal Hemorrhage
Ulcer Hemorrhage
Tumor Bleeding
Keywords: Hemospray, Gastrointestinal bleeding, Gastrointestinal hemorrhage, Hemostatic powder
Lead sponsor: Hospital Universitario Ramon y Cajal
Sponsor class: OTHER
Collaborators: name: University of Salamanca
name: Hospital del Mar
name: Puerta de Hierro University Hospital
name: Complejo Hospitalario de Navarra
name: Hospital de Henares
name: Fundación de Investigación Biomédica - Hospital Universitario de La Princesa
name: Quirón Madrid University Hospital
name: Hospital de Cruces
name: Hospital General Universitario Gregorio Marañon
name: Hospital Universitario Central de Asturias
name: Hospital Universitario de Cabuenes
name: Hospital Universitario Doctor Peset
name: Hospital del Rio Hortega
name: Hospital Universitario Madrid Sanchinarro
name: Hospital de Aviles
name: Hospital IMQ Zorrozaurre
First posted: 2018-08-02
Enrollment: 261
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with gastrointestinal bleeding treated with Hemospray®.

Brief summary: This is an observational, retrospective, analytical, and multicenter study conducted at 17 hospitals. Our research aims to assess the effectiveness of Hemospray® in patients with gastrointestinal bleeding in clinical practice. Besides, we aim to detect predictors of treatment failure defined as unsuccessful immediate hemostasis or rebleeding.


Eligibility criteria: Inclusion Criteria:

* Patients with gastrointestinal bleeding treated with Hemospray®.

Exclusion Criteria:

* None.

Primary outcomes:
measure: Hemospray® intraprocedural bleeding control
timeFrame: From Hemospray® first application up to the end of the endoscopic procedure. This variable should be assessed in day 1.
measure: Rebleeding rate
timeFrame: Date of Hemospray® application until rebleeding, assessed up to 48 months
Secondary outcomes:
measure: Adverse events potentially related to Hemospray®
timeFrame: From Hemospray application until day +7
measure: Mortality
timeFrame: From Hemospray application until death, assessed up to 48 months or lost follow-up, whichever came first
Other outcomes:
Locations:
city: Madrid
country: Spain
facility: Hospital Universitario Ramón y Cajal
Study officials:
References:
Clinical trial NCT01268904: Safety and Efficacy of Intravenous Valproate in Pediatric Status Epilepticus and Acute Repetitive Seizures
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Status Epilepticus
Lead sponsor: Hillel Yaffe Medical Center
Sponsor class: OTHER_GOV
First posted: 2010-12-31
Enrollment: 50
Sex: ALL
Minimum age (years): 6
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Pediatric inpatients and emergency patients

Brief summary: To evaluate the safety and efficacy of intravenous valproate in pediatric status epilepticus and acute repetitive seizures as part of seizure treatment protocol in pediatric ER


Eligibility criteria: Inclusion Criteria:

* Child with clinical presentation of status epilepticus

Exclusion Criteria:

* All others

Primary outcomes:
measure: Safety of intravenous valproate in pediatric status epilepticus
timeFrame: One week
Secondary outcomes:
measure: Efficacy of intravenous valproate in pediatric status epilepticus
timeFrame: One week
Other outcomes:
Locations:
city: Hadera
country: Israel
facility: Hillel Yaffe Medical Center
Study officials:
References: